28355968|t|Abiraterone - induced rhabdomyolysis resulting in acute kidney injury: A case report and review of the literature
28355968|a|Abiraterone, a CYP17 inhibitor, blocks androgen biosynthesis in multiple tissue types. In combination with prednisone, it is approved as a first-line treatment for metastatic castration-resistant prostate cancer. We present a case of rhabdomyolysis associated with abiraterone therapy resulting in acute on chronic kidney injury in a patient with metastatic castration-resistant prostate cancer. Strict monitoring should be employed in patients started on abiraterone who have additional risk factors for developing rhabdomyolysis.
28355968	0	11	Abiraterone	T103	UMLS:C0754011
28355968	22	36	rhabdomyolysis	T038	UMLS:C0035410
28355968	50	69	acute kidney injury	T037	UMLS:C2609414
28355968	73	84	case report	T170	UMLS:C0007320
28355968	89	113	review of the literature	T170	UMLS:C0282441
28355968	114	125	Abiraterone	T103	UMLS:C0754011
28355968	129	144	CYP17 inhibitor	T103	UMLS:C3160096
28355968	153	174	androgen biosynthesis	T038	UMLS:C1157302
28355968	187	193	tissue	T017	UMLS:C0040300
28355968	221	231	prednisone	T103	UMLS:C0032952
28355968	253	273	first-line treatment	T058	UMLS:C1708063
28355968	278	288	metastatic	T038	UMLS:C2939420
28355968	289	325	castration-resistant prostate cancer	T038	UMLS:C1328504
28355968	348	362	rhabdomyolysis	T038	UMLS:C0035410
28355968	379	390	abiraterone	T103	UMLS:C0754011
28355968	391	398	therapy	T058	UMLS:C0087111
28355968	412	417	acute	T037	UMLS:C2609414
28355968	429	442	kidney injury	T037	UMLS:C0160420
28355968	461	471	metastatic	T038	UMLS:C2939420
28355968	472	508	castration-resistant prostate cancer	T038	UMLS:C1328504
28355968	517	527	monitoring	T062	UMLS:C1516647
28355968	570	581	abiraterone	T103	UMLS:C0754011
28355968	602	614	risk factors	T033	UMLS:C0035648
28355968	630	644	rhabdomyolysis	T038	UMLS:C0035410